Amedeo Smart

Free Medical Literature Service


 

Amedeo

Liver Diseases

  Free Subscription

Articles published in
Clin Res Hepatol Gastroenterol
    June 2022
  1. ADDEO P, Foguenne M, Michard B, Artzner T, et al
    Emergency reversal of a Roux-en-Y Gastric bypass to rescue liver graft from recurrent steatohepatitis.
    Clin Res Hepatol Gastroenterol. 2022;46:101971.
    >> Share

  2. CHOU TP, Hu JT, Hung CS, Chen HY, et al
    Sorafenib-induced liver failure in a hepatocellular carcinoma patient: Letter to the editor.
    Clin Res Hepatol Gastroenterol. 2022;46:101931.
    >> Share

  3. BARBIER L, Cauchy F
    What assessment of the liver before resection for hepatocellular carcinoma?
    Clin Res Hepatol Gastroenterol. 2022;46:101916.
    >> Share

  4. LIU X, Luo J, Zhang L, Yang F, et al
    SIB-IMRT combined with apatinib for unresectable hepatocellular carcinoma in patients with poor response to transarterial chemoembolization.
    Clin Res Hepatol Gastroenterol. 2022;46:101897.
    >> Share

  5. WANG H, Liu D, Wang C, Yu S, et al
    Transarterial chemoembolization (TACE) plus apatinib-combined therapy versus TACE alone in the treatment of intermediate to advanced hepatocellular carcinoma patients: A real-world study.
    Clin Res Hepatol Gastroenterol. 2022;46:101869.
    >> Share

    May 2022
  6. MOREIRA-SILVA H, Amorim J, Santos-Silva E
    Incidental Liver Lesions in children: A practical and evidence-based approach.
    Clin Res Hepatol Gastroenterol. 2022;46:101904.
    >> Share

  7. ELGENIDY A, Afifi AM, Awad AK, Jalal PK, et al
    Utility of serum angiopoietin-2 as diagnostic marker of hepatocellular carcinoma: A systematic review and diagnostic test accuracy meta-analysis.
    Clin Res Hepatol Gastroenterol. 2022;46:101909.
    >> Share

  8. SHI Q, Liu J, Li T, Zhou C, et al
    Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
    Clin Res Hepatol Gastroenterol. 2022;46:101893.
    >> Share

  9. BOULOUTA A, Aggeletopoulou I, Kanaloupitis S, Tsounis EP, et al
    The impact of metabolic health on non-alcoholic fatty liver disease (NAFLD). A single center experience.
    Clin Res Hepatol Gastroenterol. 2022;46:101896.
    >> Share

  10. TRIPON S, Bilbault P, Fabacher T, Lefebvre N, et al
    Abnormal liver tests and non-alcoholic fatty liver disease predict disease progression and outcome of patients with COVID-19.
    Clin Res Hepatol Gastroenterol. 2022;46:101894.
    >> Share

  11. YOU Y, Hu S
    Aberrant expression of the esophageal carcinoma related gene 4 as a prognostic signature for hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2022;46:101891.
    >> Share

  12. ZHAO Y, Zhang C, Zhang Y, Bo C, et al
    Effects of image-guided adaptive radiotherapy combined with hepatic artery chemoembolization in primary liver cancer patients.
    Clin Res Hepatol Gastroenterol. 2022;46:101889.
    >> Share

    April 2022
  13. BOILLOT O, Chopinet S, Gregoire E, Milot L, et al
    Partial splenectomy in children undergoing liver transplantation or venous shunt for severe hypersplenism: a case control comparative study.
    Clin Res Hepatol Gastroenterol. 2022 Apr 21:101929.
    >> Share

  14. SUN L, Deng C, Gu Y, He Y, et al
    Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Clin Res Hepatol Gastroenterol. 2022;46:101876.
    >> Share

  15. ZHANG X, Jiang M, Zhang X, Zhang J, et al
    An extracellular matrix-based signature associated with immune microenvironment predicts the prognosis of patients with hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2022;46:101877.
    >> Share

  16. JAIN A, Kirkpatrick RB, Sobotka LA
    Severe pruritis during pregnancy: More than just intrahepatic cholestasis of pregnancy?
    Clin Res Hepatol Gastroenterol. 2022;46:101875.
    >> Share

  17. LI L, Xin Y, Zhang X, Chen Y, et al
    The effectiveness of radiofrequency ablation for patients with BCLC B1 stage hepatocellular carcinoma downgraded by transarterial chemoembolization.
    Clin Res Hepatol Gastroenterol. 2022;46:101878.
    >> Share

  18. HOORNAERT E, Yombi JC, Coubeau L, Baldin P, et al
    Liver hypodense infectious lesions: Is it only bacteria, parasites or fungi?
    Clin Res Hepatol Gastroenterol. 2022;46:101872.
    >> Share

  19. WASUWANICH P, So JM, Scheimann AO, Spahic H, et al
    Hepatic and non-hepatic hydrothorax in pediatric ascites.
    Clin Res Hepatol Gastroenterol. 2022;46:101868.
    >> Share

  20. ARTRU F, Moschouri E, Denys A
    Direct intrahepatic portocaval shunt (DIPS) or transjugular transcaval intrahepatic portosystemic shunt (TTIPS) to treat complications of portal hypertension: Indications, technique, and outcomes beyond Budd-Chiari syndrome.
    Clin Res Hepatol Gastroenterol. 2022;46:101858.
    >> Share

  21. WANG H, He X, Fang D, Wang X, et al
    Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model.
    Clin Res Hepatol Gastroenterol. 2022;46:101853.
    >> Share

  22. ZHANG S, Zhao Y, He L, Bo C, et al
    Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2022;46:101851.
    >> Share

  23. CANIVET CM, Smati S, Lannes A, Brisseau J, et al
    Awareness of chronic liver diseases, a comparison between diabetologists and general practitioners.
    Clin Res Hepatol Gastroenterol. 2022;46:101848.
    >> Share

  24. ZHU X, Lin X, Zhang P, Liu Y, et al
    Upregulated NLRP3 inflammasome activation is attenuated by anthocyanins in patients with nonalcoholic fatty liver disease: A case-control and an intervention study.
    Clin Res Hepatol Gastroenterol. 2022;46:101843.
    >> Share

  25. ATHYROS VG, Katsiki N, Mikhailidis DP
    Clinical benefit of statin treatment on patients with non-alcoholic fatty liver disease or steatohepatitis.
    Clin Res Hepatol Gastroenterol. 2022;46:101842.
    >> Share

  26. ZHANG C, Zhang B, Chen A, Yin Q, et al
    Trans-anethole attenuates diet-induced nonalcoholic steatohepatitis through suppressing TGF-beta-mediated fibrosis.
    Clin Res Hepatol Gastroenterol. 2022;46:101833.
    >> Share

  27. SHAHID A, Cheema HA
    Can statins finally provide the breakthrough in the treatment of non-alcoholic fatty liver disease?
    Clin Res Hepatol Gastroenterol. 2022;46:101826.
    >> Share

  28. LYU T, Yao H, Wang J, Song L, et al
    Treatment response, survival and safety profile of transarterial chemoembolization using different sizes of drug-eluting beads in hepatocellular carcinoma patients with portal vein tumor thrombus.
    Clin Res Hepatol Gastroenterol. 2022;46:101819.
    >> Share

  29. FATIMA K, Moeed A, Waqar E, Atif AR, et al
    Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2022;46:101816.
    >> Share

  30. LONCAR Y, Tartrat N, Lastennet D, Lemoine L, et al
    Pulmonary infection after hepatic resection: Associated factors and impact on outcomes.
    Clin Res Hepatol Gastroenterol. 2022;46:101733.
    >> Share

    March 2022
  31. CORDEIRO A, Ribamar A, Ramalho A
    Adipose tissue dysfunction and MAFLD in obesity on the scene of COVID-19.
    Clin Res Hepatol Gastroenterol. 2022;46:101807.
    >> Share

  32. JU S, Wang W, Chen P, Li F, et al
    Drug-eluting bead transarterial chemoembolization followed by apatinib is effective and safe in treating hepatocellular carcinoma patients with BCLC stage C.
    Clin Res Hepatol Gastroenterol. 2022;46:101859.
    >> Share

  33. DUMORTIER J, Simon M, Bouhour F
    Fatal myositis and myasthenia induced by atezolizumab for the treatment of hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2022;46:101854.
    >> Share

  34. DANA J, Girard M, Franchi-Abella S, Berteloot L, et al
    Comparison of Transient Elastography, ShearWave Elastography, Magnetic Resonance Elastography and FibroTest as routine diagnostic markers for assessing liver fibrosis in children with Cystic Fibrosis.
    Clin Res Hepatol Gastroenterol. 2022;46:101855.
    >> Share

  35. LI J, Huang WF, Zhang JY
    A rare case of duodenal neuroendocrine tumor with hepatic metastasis.
    Clin Res Hepatol Gastroenterol. 2022;46:101850.
    >> Share

  36. TANG J, Chen C, Zhou M, Wang J, et al
    NLR contributed to the diagnosis and detection of nonalcoholic fatty liver disease: A meta - analysis.
    Clin Res Hepatol Gastroenterol. 2022;46:101847.
    >> Share

  37. VALTIS YK, Barlowe T, Young JH, Lichtman AH, et al
    A woman presenting with an unusual cause of fulminant liver failure and sepsis.
    Clin Res Hepatol Gastroenterol. 2022;46:101836.
    >> Share

  38. WU D, Zhang R, Zhan L
    Transglutaminase 3 expression in hepatocellular carcinoma patients: Correlation with tumor features and survival profile.
    Clin Res Hepatol Gastroenterol. 2022;46:101812.
    >> Share

  39. TANG J, Huang Z, Xu J, Lv Q, et al
    Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
    Clin Res Hepatol Gastroenterol. 2022;46:101814.
    >> Share

  40. SCHAEFER A, Journaux M, Mourabit HE, Mouri S, et al
    A systemic mechanism of increased transendothelial migration of leukocytes through the blood-brain barrier in hepatic encephalopathy.
    Clin Res Hepatol Gastroenterol. 2022;46:101801.
    >> Share

  41. BATOOL SS, Dauer M, Weber SN, Liebe R, et al
    Intrahepatic cholestasis of pregnancy in conjunction with a frameshift deletion in FGFR4.
    Clin Res Hepatol Gastroenterol. 2022;46:101800.
    >> Share

  42. CAI Y, Wu D, Zhan L
    CCT6A expression in hepatocellular carcinoma and its correlation with clinical characteristics, liver function indexes, tumor markers and prognosis.
    Clin Res Hepatol Gastroenterol. 2022;46:101796.
    >> Share

  43. PAPAEFTHYMIOU A, Koffas A, Laskaratos FM, Epstein O, et al
    Upper gastrointestinal video capsule endoscopy: The state of the art.
    Clin Res Hepatol Gastroenterol. 2022;46:101798.
    >> Share

    February 2022
  44. THOMAS LS, Geoffroy V, Patrick C, Rodolphe A, et al
    Infectious complications of portal biliopathy leading to liver transplantation.
    Clin Res Hepatol Gastroenterol. 2022 Feb 10:101879.
    >> Share

  45. KAPS L, Hildebrand K, Nagel M, Michel M, et al
    Validation of EncephalApp_Stroop as screening tool for the detection of minimal hepatic encephalopathy in German patients with liver cirrhosis.
    Clin Res Hepatol Gastroenterol. 2022 Feb 3:101873.
    >> Share

  46. DU M, Yang S, Liu M, Liu J, et al
    COVID-19 and liver dysfunction: Epidemiology, association and potential mechanisms.
    Clin Res Hepatol Gastroenterol. 2022;46:101793.
    >> Share

  47. MACEDO MB, Giardini HAM, Pereira RMR
    A retracted diagnosis-when liver capsule retraction is not what it seems.
    Clin Res Hepatol Gastroenterol. 2022;46:101823.
    >> Share

  48. VITELLIUS C, Paisant A, Lannes A, Chaigneau J, et al
    Liver fibrosis staging by computed tomography: Prospective randomized multicentric evaluation of image analyses.
    Clin Res Hepatol Gastroenterol. 2022;46:101797.
    >> Share

  49. HE S, Chen W, Yang Y, Tang X, et al
    Adult diffuse hepatic hemangiomatosis: A case report and review of the literature.
    Clin Res Hepatol Gastroenterol. 2022;46:101789.
    >> Share

  50. WANG L, Peng Y, Qian Y, Liu Z, et al
    Transjugular extrahepatic portosystemic shunt (TEPS) creation in patients with complete occlusion of portal vein: Primary experience in a single medical center.
    Clin Res Hepatol Gastroenterol. 2022;46:101786.
    >> Share

  51. CAMPION B, Larrey E, Wagner M, Rudler M, et al
    Portal hypertension, advanced hepatocellular carcinoma and therapy by atezolizumab-bevacizumab: A "menage a trois" !
    Clin Res Hepatol Gastroenterol. 2022;46:101785.
    >> Share

  52. HUANG L, Liu J, Bie C, Liu H, et al
    Advances in cell death - related signaling pathways in acute-on-chronic liver failure.
    Clin Res Hepatol Gastroenterol. 2022;46:101783.
    >> Share

  53. LI Q, Xu H, Sui C, Zhang H, et al
    Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus.
    Clin Res Hepatol Gastroenterol. 2022;46:101781.
    >> Share

    January 2022
  54. XIN H, Zhang C, Ding Z, Zhang M, et al
    TACE plus PD-1 inhibitor (Camrelizumab) treatment for bridging to tumor resection in HCC: Case reports.
    Clin Res Hepatol Gastroenterol. 2022;46:101777.
    >> Share

  55. NAULT JC, Blanc JF, Moga L, Calderaro J, et al
    Non-invasive diagnosis and follow-up of benign liver tumours.
    Clin Res Hepatol Gastroenterol. 2022;46:101765.
    >> Share

  56. DE LEDINGHEN V
    Non-invasive diagnosis and follow-up of chronic liver disease.
    Clin Res Hepatol Gastroenterol. 2022;46:101763.
    >> Share

  57. NAHON P, Aube C, Moga L, Chalaye J, et al
    Non-invasive diagnosis and follow-up of primary malignant liver tumours.
    Clin Res Hepatol Gastroenterol. 2022;46:101766.
    >> Share

  58. CORPECHOT C, Heurgue A, Tanne F, Potier P, et al
    Non-invasive diagnosis and follow-up of primary biliary cholangitis.
    Clin Res Hepatol Gastroenterol. 2022;46:101770.
    >> Share

  59. BOURSIER J, Guillaume M, Bouzbib C, Lannes A, et al
    Non-invasive diagnosis and follow-up of non-alcoholic fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2022;46:101769.
    >> Share

  60. RAUTOU PE, Elkrief L, Decraecker M, Ollivier-Hourmand I, et al
    Non-invasive diagnosis and follow-up of vascular liver diseases.
    Clin Res Hepatol Gastroenterol. 2022;46:101764.
    >> Share

  61. SOBESKY R, Guillaud O, Bouzbib C, Sogni P, et al
    Non-invasive diagnosis and follow-up of rare genetic liver diseases.
    Clin Res Hepatol Gastroenterol. 2022;46:101768.
    >> Share

  62. BOURSIER J, Decraecker M, Bourliere M, Bureau C, et al
    Quality criteria for the measurement of liver stiffness.
    Clin Res Hepatol Gastroenterol. 2022;46:101761.
    >> Share

  63. CHEN BR, Pan CQ
    Non-invasive assessment of fibrosis and steatosis in pediatric non-alcoholic fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2022;46:101755.
    >> Share

  64. STEMPAK-DROISSART T, Rousset-Jablonski C, Spritzer PM, Lalhou N, et al
    Impact of vascular liver disease on the menstrual cycle and metabolic status in premenopausal women.
    Clin Res Hepatol Gastroenterol. 2022;46:101756.
    >> Share

  65. HOUNTONDJI L, Debourdeau A, Meunier L
    Acute liver failure secondary to Langerhans cell histiocytosis.
    Clin Res Hepatol Gastroenterol. 2022;46:101744.
    >> Share

  66. ZIMMER V, Emrich K
    Nodular gastric antral vascular ectasia: Distinct portal hypertensive hyperplastic polyp lesions.
    Clin Res Hepatol Gastroenterol. 2022;46:101745.
    >> Share

  67. DU J, Zhang J, Chen X, Zhang S, et al
    Neutrophil extracellular traps induced by pro-inflammatory cytokines enhance procoagulant activity in NASH patients.
    Clin Res Hepatol Gastroenterol. 2022;46:101697.
    >> Share

    December 2021
  68. BORIE F, Dubray V, Tretarre B
    Impact of recommendations and new therapies on the prognosis of colon cancer with synchronous liver metastasis.
    Clin Res Hepatol Gastroenterol. 2021 Dec 25:101856.
    >> Share

    November 2021
  69. SOBOTKA LA, Mumtaz K, Hinton A, Conteh LF, et al
    The Time to Advocate for Influenza Vaccines in Patients with Cirrhosis is Now.
    Clin Res Hepatol Gastroenterol. 2021 Nov 20:101838.
    >> Share

  70. MOREIRA JLS, Barbosa SMB, Goncalves Junior J
    Pathophysiology and molecular mechanisms of liver injury in severe forms of COVID-19: An integrative review.
    Clin Res Hepatol Gastroenterol. 2021;45:101752.
    >> Share

  71. THOEN RU, Longo L, Neto SC, Alvares-da-Silva MR, et al
    Low levels of Lysosomal Acid Lipase (LAL) activity increases necroinflammation in adult patients with biopsy-proven metabolic associated fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2021;45:101638.
    >> Share

  72. RUTHER DF, Sebode M, Lohse AW, Wernicke S, et al
    Mobile app requirements for patients with rare liver diseases: A single center survey for the ERN RARE-LIVER.
    Clin Res Hepatol Gastroenterol. 2021;45:101760.
    >> Share

  73. TUTUNCHI H, Naeini F, Ebrahimi-Mameghani M, Najafipour F, et al
    Metabolically healthy and unhealthy obesity and the progression of liver fibrosis: A cross-sectional study.
    Clin Res Hepatol Gastroenterol. 2021;45:101754.
    >> Share

  74. ZHAO J, Wang Y, Su H, Su L, et al
    Non-coding RNAs as biomarkers for hepatocellular carcinoma-A systematic review.
    Clin Res Hepatol Gastroenterol. 2021;45:101736.
    >> Share

  75. BLAISE L, Pereira H, Vilgrain V, Sutter O, et al
    Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasion.
    Clin Res Hepatol Gastroenterol. 2021;45:101731.
    >> Share

  76. WONG YJ, Kew GS, Tan PS, Chen Z, et al
    Novel albumin, bilirubin and platelet criteria for the exclusion of high-risk varices in compensated advanced chronic liver disease: A validation study.
    Clin Res Hepatol Gastroenterol. 2021;45:101598.
    >> Share

  77. MOTAMED N, Nikkhah M, Karbalaie Niya MH, Khoonsari M, et al
    The Ability of the Framingham Steatosis Index (FSI) to Predict Non-alcoholic Fatty Liver Disease (NAFLD): A Cohort Study.
    Clin Res Hepatol Gastroenterol. 2021;45:101567.
    >> Share

  78. BOUZBIB C, Cluzel P, Sultanik P, Bernard-Chabert B, et al
    Prognosis of patients undergoing salvage TIPS is still poor in the preemptive TIPS era.
    Clin Res Hepatol Gastroenterol. 2021;45:101593.
    >> Share

  79. HOU H, Chen D, Liu J, Feng L, et al
    Zinc monotherapy for young patients with oligosymptomatic Wilson disease: A single center, retrospective study.
    Clin Res Hepatol Gastroenterol. 2021;45:101623.
    >> Share

  80. GE J, Zhang X, Zhang B, Zhu L, et al
    Higher tumor protein kinase D1 correlates with increased tumor size, BCLC stage, CA199 level, AFP level and worse overall survival in hepatocellular carcinoma patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101573.
    >> Share

  81. LI X, Yu Y, Liu L
    Influence of aspirin use on clinical outcomes of patients with hepatocellular carcinoma: a meta-analysis.
    Clin Res Hepatol Gastroenterol. 2021;45:101545.
    >> Share

  82. VEYRE F, Dumortier J, Radenne S, Valette PJ, et al
    Rare isolated spontaneous hepatic artery thrombosis in a non-transplant patient.
    Clin Res Hepatol Gastroenterol. 2021;45:101453.
    >> Share

  83. VANDE BERG P, Borbath I, Baldin P, Vande Berg D, et al
    Granuloma formation within perihepatic lymphadenopathy.
    Clin Res Hepatol Gastroenterol. 2021;45:101504.
    >> Share

  84. ABDI SAH, Shukla S, Khan J, Al Zahrani A, et al
    Hepatotoxicity is the risk factor with gemtuzumab ozogamicin treatment in acute myelogenous leukaemia patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101443.
    >> Share

    October 2021
  85. ZHANG L, Zhou Y, Zhang J
    An incidental hepatic lesion in a cirrhotic liver.
    Clin Res Hepatol Gastroenterol. 2021 Oct 28:101825.
    >> Share

  86. MOGA L, Robic MA, Blasco-Perrin H, Cabarrou P, et al
    Acute kidney injury in patients with cirrhosis: prospective longitudinal study in 405 patients.
    Clin Res Hepatol Gastroenterol. 2021 Oct 27:101822.
    >> Share

  87. ARTZNER T, Legeai C, Antoine C, Jasseron C, et al
    Liver transplantation for critically ill cirrhotic patients: results from the French transplant registry.
    Clin Res Hepatol Gastroenterol. 2021 Oct 1:101817.
    >> Share

    September 2021
  88. CHAIBI S, Boussier J, Hajj WE, Abitbol Y, et al
    Liver function test abnormalities are associated with a poorer prognosis in Covid-19 patients: Results of a French cohort.
    Clin Res Hepatol Gastroenterol. 2021;45:101556.
    >> Share

  89. MALEZIEUX E, Meunier L, Riviere B, Larrey D, et al
    Hydrochlorothiazide-induced hepatotoxicity: A rare case of DILI.
    Clin Res Hepatol Gastroenterol. 2021;45:101599.
    >> Share

  90. CHEN S, Zhao E
    Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2021;45:101587.
    >> Share

  91. BAUMANN U, Sturm E, Lacaille F, Gonzales E, et al
    Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study.
    Clin Res Hepatol Gastroenterol. 2021;45:101751.
    >> Share

  92. WAHLIN S, Andersson J
    Liver health literacy and social stigma of liver disease: A general population e-survey.
    Clin Res Hepatol Gastroenterol. 2021;45:101750.
    >> Share

  93. LI X, Yao Q, Li R, Jin Y, et al
    Isoflurane induces liver injury by modulating the expression of miR-125a-5p.
    Clin Res Hepatol Gastroenterol. 2021;45:101732.
    >> Share

  94. BENARD J, Lafrance MJ, Gordien E, Amaral L, et al
    Hepatitis B virus-associated hepatocellular carcinoma is still a matter of concern in the French Caribbean Island of Guadeloupe.
    Clin Res Hepatol Gastroenterol. 2021;45:101706.
    >> Share

  95. YANG M, Wei S, Zhao H, Zhou D, et al
    The role of miRNA125b in the progression of hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2021;45:101712.
    >> Share

  96. LUO L, He X, Li K, Long Y, et al
    Thermal ablation of medium-sized hepatocellular carcinomas using intraoperative ultrasound fusion imaging: A propensity score-matched analysis.
    Clin Res Hepatol Gastroenterol. 2021;45:101581.
    >> Share

  97. YANG D, Wu H, Nong W, Zheng M, et al
    A new model based on gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts prognostic outcome after curative resection of solitary hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2021;45:101509.
    >> Share

  98. DE SOUSA MAGALHAES R, Xavier S, Magalhaes J, Rosa B, et al
    Transient elastography through controlled attenuated parameter assisting the stratification of cardiovascular disease risk in NAFLD patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101580.
    >> Share

  99. BOEKEN T, Gallois C, Douard R, Meatchi T, et al
    Bridge to surgery after irinotecan-based liver chemoembolization for metastatic gastric adenocarcinoma: Letter to the editor.
    Clin Res Hepatol Gastroenterol. 2021;45:101557.
    >> Share

    July 2021
  100. DUMORTIER J, Besch C, Moga L, Coilly A, et al
    NON-INVASIVE DIAGNOSIS AND FOLLOW-UP IN LIVER TRANSPLANTATION.
    Clin Res Hepatol Gastroenterol. 2021 Jul 28:101774.
    >> Share

  101. VILLERET F, Dumortier J, Erard-Poinsot D
    How will NAFLD change the liver transplant landscape in the 2020s?
    Clin Res Hepatol Gastroenterol. 2021 Jul 23:101759.
    >> Share

  102. LANTHIER N, Starkel P, Dahlqvist G
    Muscle mass depletion in chronic liver diseases: An accelerated model of aging or a distinct entity?
    Clin Res Hepatol Gastroenterol. 2021;45:101721.
    >> Share

  103. LIU W, Xu C, Meng Q, Kang P, et al
    The clinical value of kinesin superfamily protein 2A in hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2021;45:101527.
    >> Share

  104. CAMPOS-MURGUIA A, Valdez-Hernandez P, Cordova-Gallardo J, Arteaga-Vazquez J, et al
    Prevalence and clinical characteristics of alpha-1 antitrypsin deficiency in liver explants in a Mexican cohort.
    Clin Res Hepatol Gastroenterol. 2021;45:101519.
    >> Share

  105. KIM KM, Roh JH, Lee S, Yoon JH, et al
    Do renin-angiotensin system inhibitors reduce risk for hepatocellular carcinoma?: A nationwide nested case-control study.
    Clin Res Hepatol Gastroenterol. 2021;45:101510.
    >> Share

  106. CAI L, Li H, Guo J, Zhao W, et al
    Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: A cohort study.
    Clin Res Hepatol Gastroenterol. 2021;45:101535.
    >> Share

  107. SHI JY, Sun LY, Quan B, Xing H, et al
    A novel online calculator based on noninvasive markers (ALBI and APRI) for predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2021;45:101534.
    >> Share

  108. IM HJ, Ahn YC, Wang JH, Lee MM, et al
    Systematic review on the prevalence of nonalcoholic fatty liver disease in South Korea.
    Clin Res Hepatol Gastroenterol. 2021;45:101526.
    >> Share

  109. PERRAULT F, Echelard P, Viens D, Borduas M, et al
    Contraceptive vaginal ring-induced cholestasis in a patient with a history of intrahepatic cholestasis of pregnancy.
    Clin Res Hepatol Gastroenterol. 2021;45:101475.
    >> Share

  110. LIU J, Dai XL, Zhou XJ, Gu BH, et al
    Metamizole-induced acute liver failure in a boy.
    Clin Res Hepatol Gastroenterol. 2021;45:101570.
    >> Share

  111. MOSCHOURI E, Hocquelet A, Vermersch M, Fraga M, et al
    DIPS, a safe and effective alternative in patients with unfavorable anatomy to TIPSS: first experience in a tertiary center.
    Clin Res Hepatol Gastroenterol. 2021;45:101715.
    >> Share

  112. COLAK Y, Hasan B, Erkalma B, Tandon K, et al
    Pathogenetic mechanisms of nonalcoholic fatty liver disease and inhibition of the inflammasome as a new therapeutic target.
    Clin Res Hepatol Gastroenterol. 2021;45:101710.
    >> Share

  113. ILUZ-FREUNDLICH D, Grubert Van Iderstine M, Uhanova J, Zhang M, et al
    Low serum alkaline phosphatase levels in patients with chronic liver diseases: Possible contributions to disease pathogenesis.
    Clin Res Hepatol Gastroenterol. 2021;45:101694.
    >> Share

    June 2021
  114. QU Y, Li T, Lin C, Liu F, et al
    Animal Naming Test for the Assessment of Minimal Hepatic Encephalopathy in Asian Cirrhotic Populations.
    Clin Res Hepatol Gastroenterol. 2021 Jun 3:101729.
    >> Share

  115. RAZAQ S, Kara M, Ozcakar L
    Measure Grip Strength, Gait Speed and Quadriceps Muscle in Cirrhosis. Comment to "Frailty, sarcopenia and mortality in cirrhosis: What is the best assessment, how to interpret the data correctly and what interventions are possible?"
    Clin Res Hepatol Gastroenterol. 2021 Jun 1:101727.
    >> Share

    May 2021
  116. VUJAKLIJA BRAJKOVIC A, Zlopasa O, Gubarev Vrdoljak N, Goran T, et al
    Acute liver and cardiac failure in multisystem inflammatory syndrome in adults after COVID-19.
    Clin Res Hepatol Gastroenterol. 2021;45:101678.
    >> Share

  117. SERRA F, Bonaduce I, De Ruvo N, Cautero N, et al
    Covid-19 and hepatic injury: A systematic review.
    Clin Res Hepatol Gastroenterol. 2021;45:101605.
    >> Share

  118. SHIHA G, Soliman R, Mikhail N, Zaky S, et al
    HCC developed in CHC patients who achieved SVR following DAAs tend to display less aggressive pattern.
    Clin Res Hepatol Gastroenterol. 2021;45:101608.
    >> Share

  119. WORLAND T, O'Neill P, Rusli F
    Resolution of metastatic hepatocellular carcinoma with sour cherry intake.
    Clin Res Hepatol Gastroenterol. 2021;45:101663.
    >> Share

  120. DEVICTOR J, Leclercq A, Hazo JB, Burnet E, et al
    Nurse coordinator roles in the management of patients with hepatocellular carcinoma: A French national survey.
    Clin Res Hepatol Gastroenterol. 2021;45:101650.
    >> Share

  121. MU X, Tong J, Xu X, Chen J, et al
    World Gastroenterology Organisation classification and a new type-based prognostic model for hepatitis B virus-related acute-on-chronic liver failure.
    Clin Res Hepatol Gastroenterol. 2021;45:101548.
    >> Share

  122. ARAZ M, Kilinc F, Kerimoglu U, Keskin M, et al
    Irinotecan-induced NASH and liver failure.
    Clin Res Hepatol Gastroenterol. 2021;45:101606.
    >> Share

  123. KALOGIROU MS, Patoulias D, Haidich AB, Akriviadis E, et al
    Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.
    Clin Res Hepatol Gastroenterol. 2021;45:101568.
    >> Share

  124. LIN M, Zeng H, Deng G, Lei J, et al
    Vitamin E in paediatric non-alcoholic fatty liver disease: a meta-analysis.
    Clin Res Hepatol Gastroenterol. 2021;45:101530.
    >> Share

  125. KARNSAKUL W, Wasuwanich P, Ingviya T, Laengvejkal P, et al
    Clinical usage of serum albumin to ascitic fluid albumin gradient and ascitic fluid total protein in pediatric ascites.
    Clin Res Hepatol Gastroenterol. 2021;45:101549.
    >> Share

  126. KARATAS E, Bouchecareilh M
    Alpha 1-Antitrypsin deficiency in liver explants in a Mexican cohort: A unique cohort to assess the role of heterozygous genotypes in liver disease.
    Clin Res Hepatol Gastroenterol. 2021;45:101538.
    >> Share

  127. DE MUNCK TJI, Verhaegh P, Lodewick T, Bakers F, et al
    Myosteatosis in nonalcoholic fatty liver disease: An exploratory study.
    Clin Res Hepatol Gastroenterol. 2021;45:101500.
    >> Share

  128. DE VOS N, Van der Meulen J, Van Der Linden M, Claes K, et al
    Myxoid hepatocellular adenoma, a rare variant of hepatocellular adenoma with distinct imaging features: A case report with immunohistochemical and molecular analysis and literature review.
    Clin Res Hepatol Gastroenterol. 2021;45:101478.
    >> Share

  129. LYKAVIERIS P, Bernard O, Jacquemin E
    Ursodeoxycholic acid therapy throughout pregnancy in women affected with chronic cholestasis of childhood: No evidence for teratogenicity.
    Clin Res Hepatol Gastroenterol. 2021;45:101472.
    >> Share

  130. RIVAS M, Aguiar T, Fernandes G, Lemes R, et al
    DNA methylation as a key epigenetic player for hepatoblastoma characterization.
    Clin Res Hepatol Gastroenterol. 2021;45:101684.
    >> Share

  131. BOILLOT O, Cayot B, Guillaud O, Crozet-Chaussin J, et al
    Partial major hepatectomy with cyst fenestration for polycystic liver disease: Indications, short and long-term outcomes.
    Clin Res Hepatol Gastroenterol. 2021;45:101670.
    >> Share

  132. KULKARNI AV, Tevethia HV, Arab JP, Candia R, et al
    Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2021;45:101675.
    >> Share

  133. ZAREBSKA I, Gzil A, Durslewicz J, Jaworski D, et al
    The clinical, prognostic and therapeutic significance of liver cancer stem cells and their markers.
    Clin Res Hepatol Gastroenterol. 2021;45:101664.
    >> Share

    April 2021
  134. OZCELIK F
    Prognostic value of gamma-glutamyl transpeptidase in liver cirrhosis and hepatocellular cancer regardless of other parameters.
    Clin Res Hepatol Gastroenterol. 2021 Apr 27:101708.
    >> Share

  135. CARDOSO CC, Matiollo C, Pereira CHJ, Fonseca JS, et al
    B-cell compartment abnormalities are associated with ACLF and mortality in patients with liver cirrhosis.
    Clin Res Hepatol Gastroenterol. 2021 Apr 11:101698.
    >> Share

    March 2021
  136. TORNAI D, Vitalis Z, Jonas A, Janka T, et al
    Increased sTREM-1 levels identify cirrhotic patients with bacterial infection and predict their 90-day mortality.
    Clin Res Hepatol Gastroenterol. 2021;45:101579.
    >> Share

  137. CAO X, Cao Z, Ou C, Zhang L, et al
    Combination of serum paraoxonase/arylesterase 1 and antithrombin-III is a promising non-invasion biomarker for discrimination of AFP-negative HCC versus liver cirrhosis patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101583.
    >> Share

  138. CORPECHOT C
    The revival of preemptive UDCA therapy in liver transplant recipients: Commentary to "UDCA decreases Incidence of Primary Biliary Cholangitis and Biliary Complications after Liver Transplant: A Meta-Analysis" by Pedersen et al., Liver Transplant, Nove
    Clin Res Hepatol Gastroenterol. 2021 Mar 13:101679.
    >> Share

  139. ALTIERI M, Seree O, Lobbedez T, Segol P, et al
    Risk factors of de novo malignancies after liver transplantation: a French national study on 11004 adult patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101514.
    >> Share

  140. LANTHIER N, Starkel P, Dahlqvist G
    Frailty, sarcopenia and mortality in cirrhosis: what is the best assessment, how to interpret the data correctly and what interventions are possible?
    Clin Res Hepatol Gastroenterol. 2021 Mar 2:101661.
    >> Share

  141. COUPIER A, Pioche M, Steer N, Zoulim F, et al
    An exceptional case of refractory variceal bleeding occurring during liver transplantation rescued with esophageal stent.
    Clin Res Hepatol Gastroenterol. 2021 Mar 2:101662.
    >> Share

  142. BLANC JF, Debaillon-Vesque A, Roth G, Barbare JC, et al
    Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI).
    Clin Res Hepatol Gastroenterol. 2021;45:101590.
    >> Share

  143. TIAN J, Hu D
    LncRNA SLC16A1-AS1 is upregulated in hepatocellular carcinoma and predicts poor survival.
    Clin Res Hepatol Gastroenterol. 2021;45:101490.
    >> Share

  144. SOBOTKA LA, Chen JL, Wellner MR
    Compression induced hepatic injury: an unusual case of abnormal liver function tests.
    Clin Res Hepatol Gastroenterol. 2021;45:101655.
    >> Share

  145. LIU Y, Wu H, Wang Z, Wu J, et al
    Integrated expression profiles of mRNA and miRNA in a gerbil model of fatty liver fibrosis treated with exenatide.
    Clin Res Hepatol Gastroenterol. 2021;45:101312.
    >> Share

  146. SU Q, Wang H
    Long non-coding RNA 01559 mediates the malignant phenotypes of hepatocellular carcinoma cells through targeting miR-511.
    Clin Res Hepatol Gastroenterol. 2021;45:101648.
    >> Share

  147. ROSSO C, Caviglia GP, Armandi A, Ribaldone DG, et al
    Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease?
    Clin Res Hepatol Gastroenterol. 2021;45:101611.
    >> Share

  148. XIE Z, Wu Y, Liu S, Lai Y, et al
    LncRNA-SNHG7/miR-29b/DNMT3A axis affects activation, autophagy and proliferation of hepatic stellate cells in liver fibrosis.
    Clin Res Hepatol Gastroenterol. 2021;45:101469.
    >> Share

  149. MAZZOLA A, Magro B, Perdigao F, Charlotte F, et al
    Acute liver failure and HELLP syndrome: A clinical case and literature review.
    Clin Res Hepatol Gastroenterol. 2021;45:101498.
    >> Share

  150. SHEN X, Huang Y, Guo H, Peng H, et al
    Oral ibuprofen promoted cholestatic liver disease in very low birth weight infants with patent ductus arteriosus.
    Clin Res Hepatol Gastroenterol. 2021;45:101495.
    >> Share

  151. XU X, Hou Z, Xu Y, Gu H, et al
    The dynamic of platelet count as a novel and valuable predictor for 90-day survival of hepatitis B virus-related acute-on-chronic liver failure patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101482.
    >> Share

  152. CHEN C, Qiu H, Yao Y, Zhang Z, et al
    Comprehensive predictive factors for CalliSpheres(R) microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101460.
    >> Share

  153. TURPIN A, de Baere T, Heurgue A, Le Malicot K, et al
    Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study.
    Clin Res Hepatol Gastroenterol. 2021;45:101464.
    >> Share

    February 2021
  154. GAO Y, Liu H, Tang F, Zhang X, et al
    Efficacy and safety of anticoagulants in liver cirrhosis patients with portal vein thrombosis: A meta-analysis.
    Clin Res Hepatol Gastroenterol. 2021 Feb 15:101649.
    >> Share

    January 2021
  155. ZHAO N, Liu X, Guo H, Zhao X, et al
    Interleukin-35: An emerging player in the progression of liver diseases.
    Clin Res Hepatol Gastroenterol. 2021;45:101518.
    >> Share

  156. CHARPY F, Debourdeau A, Boivineau L, Meszaros M, et al
    Hepatic amyloidosis as a case of fatal fulminant liver failure.
    Clin Res Hepatol Gastroenterol. 2021;45:101506.
    >> Share

  157. BRAUNER C, Joveleviths D, Alvares-da-Silva MR
    Hepatotoxicity by methyl methacrylate.
    Clin Res Hepatol Gastroenterol. 2021;45:101513.
    >> Share

  158. THEVENOT T, Savale L, Sitbon O
    Portopulmonary hypertension: An unfolding story.
    Clin Res Hepatol Gastroenterol. 2021;45:101492.
    >> Share

  159. WANG J, Feng L, Zhang L
    Combining cellular immunotherapy was an optional choice for unresectable advanced HCC: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2021;45:101440.
    >> Share

  160. LEMAITRE C, Thiebaut PA, Francois A, Michel P, et al
    An unexpected cause of heterogeneous liver.
    Clin Res Hepatol Gastroenterol. 2021;45:101444.
    >> Share

  161. KANG Y, Park S, Kim S, Han SJ, et al
    Validating the BAVENO VI criteria to identify low risk biliary atresia patients without endoscopy for esophageal varix.
    Clin Res Hepatol Gastroenterol. 2021;45:101437.
    >> Share

  162. RAFFETTI E, Portolani N, Molfino S, Mentasti S, et al
    Is survival for hepatocellular carcinoma increasing? A population-based study on survival of hepatocellular carcinoma patients in the 1990s and 2000s.
    Clin Res Hepatol Gastroenterol. 2021;45:101433.
    >> Share

  163. CHANG Y, He J, Xiang X, Li H, et al
    LUM is the hub gene of advanced fibrosis in nonalcoholic fatty liver disease patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101435.
    >> Share

    November 2020
  164. HUANG C, Seah JJ, Tan CK, Kam JW, et al
    Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2020 Nov 29:101528.
    >> Share

  165. BEST MG, Wurdinger T
    Tumor-educated platelets for the earlier detection of hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2020;44:794-795.
    >> Share

    October 2020
  166. WANG H, Qiu P, Liu J, Wang F, et al
    The liver injury and gastrointestinal symptoms in patients with Coronavirus Disease 19: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2020;44:653-661.
    >> Share

  167. RAHAL HK, Tabibian JH
    The MBOAT7 rs641738 variant in primary sclerosing cholangitis: A novel biomarker for prognostication.
    Clin Res Hepatol Gastroenterol. 2020;44:619-621.
    >> Share

    September 2020
  168. ALI N
    Is SARS-CoV-2 associated with liver dysfunction in COVID-19 patients?
    Clin Res Hepatol Gastroenterol. 2020;44:e84-e86.
    >> Share

    August 2020
  169. ELKRIEF L, Houssel-Debry P, Ackermann O, Franchi-Abella S, et al
    Portal cavernoma or chronic non cirrhotic extrahepatic portal vein obstruction.
    Clin Res Hepatol Gastroenterol. 2020 Aug 17. pii: S2210-7401(20)30091.
    >> Share

    July 2020
  170. TRIPON S, Mayer P, Svab A, Habersetzer F, et al
    Intraabdominal urokinase in the treatment of loculated infected ascites in cirrhosis.
    Clin Res Hepatol Gastroenterol. 2020 Jul 9. pii: S2210-7401(20)30181.
    >> Share

    June 2020
  171. DE GOTTARDI A, Fratila C, Bertoli R, Cerny A, et al
    Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection.
    Clin Res Hepatol Gastroenterol. 2020 Jun 10. pii: S2210-7401(20)30159.
    >> Share

  172. GANNE-CARRIE N, Fontaine H, Dumortier J, Boursier J, et al
    Suggestions for the care of patients with liver disease during the Coronavirus 2019 pandemic.
    Clin Res Hepatol Gastroenterol. 2020;44:275-281.
    >> Share

    April 2020
  173. ABERGEL A, Gasperment M, Nery FG, Buchard B, et al
    Extrahepatic portal vein obstruction (EHPVO) in cirrhosis.
    Clin Res Hepatol Gastroenterol. 2020 Apr 17. pii: S2210-7401(20)30089.
    >> Share

  174. JANKOWSKA I, Czubkowski P, Rokicki D, Lipinski P, et al
    Acute liver failure due to DGUOK deficiency-is liver transplantation justified?
    Clin Res Hepatol Gastroenterol. 2020 Apr 8. pii: S2210-7401(20)30082.
    >> Share

    March 2020
  175. FELLI E, Baumert T, Pessaux P
    Is minimally invasive true anatomical HCC resection a future way to improve results in bridge or salvage liver transplantation?
    Clin Res Hepatol Gastroenterol. 2020 Mar 18. pii: S2210-7401(20)30049.
    >> Share

  176. MORANDEAU E, Rayer C, Jezequel C, Guyader D, et al
    Hepatic encephalopathy post liver transplantation.
    Clin Res Hepatol Gastroenterol. 2020 Mar 10. pii: S2210-7401(20)30039.
    >> Share

    January 2020
  177. PETA V, Zhu J, Lubman DM, Huguet S, et al
    Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease.
    Clin Res Hepatol Gastroenterol. 2020 Jan 18. pii: S2210-7401(19)30272.
    >> Share

  178. HEDJOUDJE A, Cervoni JP, Patry C, Chatot M, et al
    Takotsubo cardiomyopathy triggered by delirium tremens in a cirrhotic patient with acute-on-chronic liver failure: A case report.
    Clin Res Hepatol Gastroenterol. 2020 Jan 9. pii: S2210-7401(19)30262.
    >> Share

    December 2019
  179. GOUMARD C, Scatton O
    Resectable HCC: Should salvage liver transplantation for HCC be discussed de principe?
    Clin Res Hepatol Gastroenterol. 2019 Dec 18. pii: S2210-7401(19)30251.
    >> Share

    November 2019
  180. ALLAIRE M, Cadranel JF, Nguyen TTN, Garioud A, et al
    Management of infections in patients with cirrhosis in the context of increasing therapeutic resistance: A systematic review.
    Clin Res Hepatol Gastroenterol. 2019 Nov 6. pii: S2210-7401(19)30224.
    >> Share

    October 2019
  181. ALLAIRE M, Walter A, Sutter O, Nahon P, et al
    TIPS for management of portal-hypertension-related complications in patients with cirrhosis.
    Clin Res Hepatol Gastroenterol. 2019 Oct 26. pii: S2210-7401(19)30217.
    >> Share

    August 2019
  182. WANLESS IR
    Quantitative SHG-microscopy: Unraveling the nano-architecture of the cirrhotic liver.
    Clin Res Hepatol Gastroenterol. 2019 Aug 12. pii: S2210-7401(19)30174.
    >> Share

    June 2019
  183. LIBERAL R, Gaspar R, Lopes S, Macedo G, et al
    Primary biliary cholangitis in patients with inflammatory bowel disease.
    Clin Res Hepatol Gastroenterol. 2019 Jun 3. pii: S2210-7401(19)30099.
    >> Share

    April 2019
  184. SCHIELKE A, Scatton O, Boelle PY, Perdigao F, et al
    Ischemic-type biliary lesions: A leading indication of liver retransplantation with excellent results.
    Clin Res Hepatol Gastroenterol. 2019;43:131-139.
    >> Share

  185. MURATORI P, Lenzi M, Muratori L
    Diagnosis of primary biliary cholangitis in a "teen" male patient.
    Clin Res Hepatol Gastroenterol. 2019;43:e20-e21.
    >> Share

    March 2019
  186. YANG F, Ren H, Gao Y, Zhu Y, et al
    The value of severe vitamin D deficiency in predicting the mortality risk of patients with liver cirrhosis: A meta-analysis.
    Clin Res Hepatol Gastroenterol. 2019 Mar 29. pii: S2210-7401(19)30052.
    >> Share

  187. MAESTAS C, Lazkani M, Sultan M, Kolli G, et al
    Severe takotsubo cardiomyopathy following orthotopic liver transplantation: A case series.
    Clin Res Hepatol Gastroenterol. 2019 Mar 7. pii: S2210-7401(18)30266.
    >> Share

  188. QU W, Zhu ZJ, Wei L, Sun LY, et al
    Feasibility of domino liver transplantation from hyperhomocsyteinemia.
    Clin Res Hepatol Gastroenterol. 2019 Mar 7. pii: S2210-7401(19)30039.
    >> Share

    January 2019
  189. LEBRAY P, Varnous S
    Combined heart and liver transplantation: State of knowledge and outlooks.
    Clin Res Hepatol Gastroenterol. 2019 Jan 8. pii: S2210-7401(18)30173.
    >> Share

    December 2018
  190. BERGERE M, Erard-Poinsot D, Boillot O, Valette PJ, et al
    Portal vein thrombosis and liver cirrhosis: Long-term anticoagulation is effective and safe.
    Clin Res Hepatol Gastroenterol. 2018 Dec 18. pii: S2210-7401(18)30268.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016